Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
If you are considering NK cell therapy, most of the conversation naturally focuses on the infusion itself. Yet a large part of the process happens before that day, in a laboratory you may never see. Your own NK cells are collected from a blood draw, activated and expanded outside the body, and then returned by IV infusion. This article explains, in plain language, what happens during that processing stage and which questions are reasonable to raise at Grand Green Osaka Umekita Clinic or any clinic you are comparing.
Short answer: what happens between the blood draw and the infusion
NK (natural killer) cells are a type of lymphocyte that circulates in the blood and can detect abnormal cells, including cancer cells and virus-infected cells, without waiting for instructions from other immune cells. In NK cell therapy, a sample of your blood is taken in a standard blood draw. The NK cells are then activated and expanded at a specialized cell processing facility so that a larger number of more active cells can be returned to you by IV infusion.
The aim is to reinforce immune function that may have weakened, for example with age, stress, or the effects of cancer itself. It is not a guarantee of any particular outcome, and it is not a replacement for standard cancer treatment. Whether it fits your situation is a decision that needs a doctor’s consultation.
Why the processing stage matters to patients
Because the therapy uses your own cells, the quality of the handling process is a central part of the treatment. The cells are living material. How they are collected, transported, cultured, checked, and returned all shape what you ultimately receive. Patients often focus on the clinic, but it is equally reasonable to ask where and under what rules the cells are prepared.
In Japan, cell therapies of this type are provided under the regenerative medicine law. Under this framework, a clinic submits a treatment plan that is reviewed and accepted by the authorities, and cell processing is expected to take place at a facility that meets legal requirements. This is a structure for oversight, not a promise of results, and it is worth asking your doctor to explain how it applies to the specific plan you are being offered.
Questions to ask about the cell processing facility
You do not need a scientific background to ask useful questions. The following points help you understand how the process is organized before you decide anything.
- Where are the cells processed, and is that facility licensed or registered under Japanese regulations for cell processing?
- Which treatment plan covers the therapy, and how can you confirm that the plan has been accepted by the authorities?
- How are your blood sample and the finished cells transported, and how is the identity of each patient’s cells tracked?
- What checks are carried out on the cells before they are returned, and what happens if a batch does not meet the criteria?
- Which doctor is responsible for reviewing the results and explaining them to you?
A clinic that welcomes these questions and answers them clearly gives you useful information about how the treatment is run. If an answer is vague, it is fine to ask for it in writing or to take more time before deciding.
What this means for the timeline and daily life
Cell activation and expansion take time, so NK cell therapy is not a same-day treatment. The blood draw and the later IV infusion are each fairly simple procedures with no hospital stay, which is why many people continue their daily routines during treatment. Temporary reactions such as fever or fatigue may occur after an infusion, and serious side effects have rarely been reported, but individual responses differ and your doctor will explain what to watch for.
If you are traveling from overseas, the processing period matters for planning. Ask how many visits are involved, how long the interval between the blood draw and the infusion is expected to be, and how your follow-up will be arranged after you return home. These practical details differ between plans, so confirm them directly rather than relying on general descriptions.
Coordinating with your standard cancer care
NK cell therapy is generally considered alongside surgery, chemotherapy, or radiation therapy rather than instead of them, but whether and when to combine them is a medical judgment. Your oncologist’s treatment schedule can affect when a blood sample should be collected and when an infusion is appropriate. Grand Green Osaka Umekita Clinic can coordinate with the medical institution providing your standard treatment, and bringing your latest records to the consultation helps the doctor assess your situation.
Please keep in mind that this therapy is one option to understand, not a substitute for the treatment recommended by your cancer team. Decisions about starting, pausing, or combining treatments should always involve both doctors.
Costs, risks, and where to get more information
NK cell therapy is a self-pay (non-insured) treatment in Japan. Fees, the number of treatments, the treatment period, possible risks and side effects, and whether you are a suitable candidate are all confirmed at a doctor’s consultation. Reviewing the fee information and the frequently asked questions on the clinic’s NK cell therapy page before your appointment helps you prepare.
Grand Green Osaka Umekita Clinic is located in Umeda, Osaka, and provides an information page for international patients so that overseas visitors and residents can review the basics in English. If you are weighing several options, writing down the questions above and bringing them to your consultation is a practical way to get clear, comparable answers.
- 1Blood drawStandard blood sample
- 2Cell processingActivation and expansion
- 3ChecksAsk what is reviewed
- 4IV infusionCells returned to you
This diagram is a conceptual summary of the article content
References
- PubMed: Generating natural killer cells for adoptive transfer: expanding horizons. (2021)
- PubMed: Umbilical cord blood-derived CAR-NK cells: an emerging off-the-shelf platform for cancer immunotherapy. (2026)
- PubMed: Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy. (2018)
- PubMed: Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells. (2017)
- PubMed: How do we manufacture clinical-grade interleukin-15-stimulated natural killer cell products for cancer treatment? (2018)
- PMC: Umbilical cord blood natural killer cells for adoptive immunotherapy: identifying optimal starting material and processing parameters. (2025)
- PMC: Process engineering of natural killer cell-based immunotherapy. (2023)
- PMC: Application of natural killer immunotherapy in blood cancers and solid tumors. (2023)
- MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.